Group 1 - The National Drug Administration of China announced that by 2025, the country is expected to approve 76 innovative drugs, ranking first globally [2] - The approval process reforms have effectively stimulated innovation in the pharmaceutical industry, leading to a projected total transaction volume of over $130 billion for Chinese innovative drug BD (business development) overseas licensing in the same year [2] - The Hong Kong Stock Connect Innovative Drug Index (987018) showed strong performance with significant gains in constituent stocks, indicating positive market sentiment towards innovative pharmaceuticals [1] Group 2 - Positive clinical data for small nucleic acid drugs has been reported, with ongoing optimism for the innovative drug sector [2] - Arrowhead Pharmaceuticals released mid-term data for ARO-INHBE and ARO-ALK7, demonstrating efficacy in patients with T2D obesity, which enhances market confidence in small nucleic acids for weight management [2] - The recent listing of Reborna Bio on the Hong Kong Stock Exchange has seen active stock performance, with its core pipeline targeting thrombotic diseases, indicating a promising market potential exceeding $50 billion [2]